Epcoritimab is a treatment for diffuse large B-cell lymphoma, a form of Non-Hodgkin lymphoma affecting ... and I’m so grateful to be alive. I live in a lovely place, and I’m thankful, but ...

Future research into non-Hodgkin lymphoma treatments needs to explore long-term outcomes and a better understanding biologic ...

The investigation demonstrated that dual targeting of DOT1L and EZH2 effectively prevented human GCB-DLBCL xenograft growth ...

Five diagnosed prevalent cases will grow to over 714,000. Diagnosed incident cases of B-cell non-Hodgkin’s lymphoma (B-cell NHL) across the seven major markets (7MM) are expected to increase from 200, ...

in 83% of patients with indolent relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) comparing favorably to 34% historical CR rate with R 2 alone - Phase 2 portion of trial in patients with ...

Has come back (relapsed) within a year of treatment or does not go away (refractory) after your first treatment Has relapsed or is refractory and you cannot receive a hematopoietic stem cell ...

Lymphomas belong to the group of malignant diseases of the immune system and mainly affect the organs of the lymphatic system. Anaplastic large cell lymphoma (ALCL) belongs to the subgroup of ...

A next-generation "armored" CAR T cell therapy showed promising results in a small study of patients whose B-cell lymphomas ...

Non-Hodgkin ... cells in the lymphatic system. They are generally classified according to the cancer's growth rate as high grade (fast growing) or low grade (slow growing). Diffuse large B-cell ...